Circulating endotrophin correlates with myocardial extracellular volume and is reduced by pirfenidone therapy, highlighting its potential as a biomarker for myocardial fibrosis in HFpEF.
Does pirfenidone reduce circulating endotrophin levels, and is endotrophin associated with myocardial ECV in patients with HFpEF?
Patients with heart failure with preserved ejection fraction (HFpEF)
Pirfenidone
Circulating levels of endotrophin and myocardial extracellular volume (ECV)surrogate
Circulating endotrophin is a promising biomarker for myocardial fibrosis burden that is sensitive to antifibrotic therapy with pirfenidone in HFpEF.
Absolute Event Rate: 0% vs 0%
In patients with heart failure with preserved ejection fraction, treatment with pirfenidone was associated with a sustained reduction in circulating levels of endotrophin from 13 weeks. Circulating endotrophin was also independently associated with both baseline myocardial ECV and change in myocardial ECV. Endotrophin shows high potential as a circulating biomarker reflective of myocardial fibrosis burden and sensitive to change in myocardial fibrosis over time.
Building similarity graph...
Analyzing shared references across papers
Loading...
Nicholas Black
Gavin Lewis
Fardad Soltani
JACC Advances
University of Liverpool
Manchester Academic Health Science Centre
Royal Liverpool University Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Black et al. (Fri,) reported a other. Circulating endotrophin correlates with myocardial extracellular volume and is reduced by pirfenidone therapy, highlighting its potential as a biomarker for myocardial fibrosis in HFpEF.
synapsesocial.com/papers/69e7132bcb99343efc98cda9 — DOI: https://doi.org/10.1016/j.jacadv.2026.102738
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: